Wikipedia
Aducanumab
Aducanumab is the given USAN and INN name for a biopharmaceutical, the human monoclonal antibody and drug candidate BIIB037 designed for treatment of Alzheimer's disease (AD). It is being developed by Biogen Idec, which licensed the drug candidate from Neurimmune, its discoverer. The antibody targets aggregated forms of beta amyloid. Interim results from the second Phase 1 study of the drug were reported at the 12th International Conference on Alzheimer’s and Parkinsons’s Diseases and Related Neurological Disorders (AD/PD 2015), in Nice, France, in March 2015.